

Neurofibromatosis Type 1 Genetic Testing

EviCore
By EVERNORTH

- This benefit/harm statement only applies to those jurisdictions that do not have Medicare guidance.
- Based upon the guidelines and evidence provided in the clinical policy, following EviCore's criteria for Neurofibromatosis Type 1 testing will ensure that testing will be available to those members most likely to benefit from a genetic diagnosis. For those not meeting criteria, it ensures alternate diagnostic strategies are considered. However, it is possible that some members who have the condition, but have non-standard features, will not receive an immediate approval for testing.